Mission Therapeutics Gets $32M Financing for Hitting Dubs
By Cormac Sheridan
Monday, November 18, 2013
Mission Therapeutics Ltd. landed £20 million (US$32 million) in second-round funding, evidence that some European investors still have a substantial appetite for preclinical biotechnology firms working in a cutting-edge area of science.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.